1. Statistics Canada. Table 103-0550: new cases of primary cancer (based on the July 2016 CCR tabulation file), by cancer type, age group and sex, Canada, provinces and territories. 2015.
http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=1030550
. Accessed Sep 2017.
2. Brandwein JM, Geddes M, Kassis J, et al. Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. Am J Blood Res. 2013;3:141–64.
3. Schuh AC, Fletcher GG, Leber B, et al. Systemic treatment of acute myeloid leukemia (AML). Program in evidence-based care guideline No.: 12–9. 2016.
https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/pebc12-9f.pdf
. Accessed Nov 2018.
4. Cancer, Leukemia Group B, Farag SS, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63–73.
5. Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age > or = 75 years. Cancer. 2004;101:325–31.